Iratumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Iratumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD30
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6358H9830N1682O1992S38
Molar mass170 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]

This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.

The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.[2]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
  2. ^ "Iratumumab". AdisInsight. Retrieved 30 January 2017.